NPS Pharma has posted net loss of $6.13m, compared to $6.3m for the same period in the prior year.
The company’s operating income was $4.04m for the second quarter ended 30 June 2011, against $4.03m for the same period in 2010.
NPS Pharma president and CEO Francois Nader said their clinical, regulatory and technical operations teams are on track with the execution of the two Phase 3 registration programs for Gattex and NPSP558.
"We expect to report results from the Phase 3 Replace clinical study of NPSP558 in patients with hypoparathyroidism in the fourth quarter and pursue US registration of the drug if study results are positive," Nader said.